Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Biomedical Sciences

• Publication date

  2004-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF02256568PMID 14966375
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway.

  2003cited by this paper
• Quantification of vascular endothelial growth factor-C and its receptor-3 messenger RNA with real-time quantitative polymerase chain reaction as a predictor of lymph node metastasis in human colorectal cancer.

  2003cited by this paper
• Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma

  2003cited by this paper
• Up-regulation of Vascular Endothelial Growth Factor C in Breast Cancer Cells by Heregulin-β1

  2003cited by this paper
• Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy.

  2002cited by this paper
• Ligand-induced, receptor-mediated dimerization and activation of EGF receptor.

  2002cited by this paper
• C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors.

  2002cited by this paper
• Induction of ovarian cancer by defined multiple genetic changes in a mouse model system.

  2002cited by this paper
• ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma

  2002cited by this paper
• Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer.

  2002cited by this paper
• Advances in the treatment of gynecologic malignancies. Part 2: Cancers of the uterine corpus and ovary.

  2002cited by this paper
• Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.

  2001cited by this paper
• HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression

  2001cited by this paper
• Her-2/neu overexpression induces NF-κB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IκB-α that can be inhibited by the tumor suppressor PTEN

  2001cited by this paper
• The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer

  2001cited by this paper
• Akt Stimulates the Transactivation Potential of the RelA/p65 Subunit of NF-κB through Utilization of the IκB Kinase and Activation of the Mitogen-activated Protein Kinase p38*

  2001cited by this paper
• Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth.

  2001cited by this paper
• Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer

  2001cited by this paper
• Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3

  2001cited by this paper
• Overexpression of HER-2 in ovarian carcinomas.

  2001cited by this paper
• Signalling via vascular endothelial growth factor receptor‐3 is sufficient for lymphangiogenesis in transgenic mice

  2001cited by this paper
• HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway.

  2000cited by this paper
• Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma.

  2000cited by this paper
• Ovarian cancer: epidemiology, biology, and prognostic factors.

  2000cited by this paper
• HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway*

  2000cited by this paper
• Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-κB/Rel− specific decoy oligodeoxynucleotides

  2000cited by this paper
• Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells.

  2000cited by this paper
• Evaluation of cytoreductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer.

  1999cited by this paper
• PIK3CA is implicated as an oncogene in ovarian cancer

  1999cited by this paper
• Basic science of HER-2/neu: a review.

  1999cited by this paper
• Overexpression of the Oncogene c‐erbB-2 (HER2/neu) and Response to Chemotherapy in Patients with Ovarian Cancer

  1998cited by this paper
• A Recombinant Mutant Vascular Endothelial Growth Factor-C that Has Lost Vascular Endothelial Growth Factor Receptor-2 Binding, Activation, and Vascular Permeability Activities*

  1998cited by this paper
• Proinflammatory Cytokines Regulate Expression of the Lymphatic Endothelial Mitogen Vascular Endothelial Growth Factor-C*

  1998cited by this paper
• Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization.

  1998cited by this paper
• Genomic Organization of Human and Mouse Genes for Vascular Endothelial Growth Factor C*

  1997cited by this paper
• A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.

  1996cited by this paper
• A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases.

  1996cited by this paper
• Overexpression of c‐erbB‐2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy

  1995cited by this paper
• Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients.

  1995cited by this paper
• Poly(adenosine diphosphoribose) polymerase in peripheral blood leukocytes from normal donors and patients with malignancies.

  1995cited by this paper
• Prognostic significance of HER‐2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis

  1993cited by this paper
• Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells.

  1990cited by this paper
• Site-Directed Insertion of Long Single-Stranded DNA Fragments into Plasmid DNA

  1990cited by this paper
• Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

  1990cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper

• Relationship of HER-2 Overexpression with Size and Stage of Tumor In Patients With Primary Breast Carcinoma

  2025cites this paper
• Lymphatic vessel: Origin, heterogeneity, biological functions and therapeutic targets

  2024cites this paper
• Cancer-Associated Membrane Protein as Targeted Therapy for Bladder Cancer

  2022cites this paper
• Combination of Immune-Related Genomic Alterations Reveals Immune Characterization and Prediction of Different Prognostic Risks in Ovarian Cancer

  2021cites this paper
• Antrodia salmonea‐induced oxidative stress abrogates HER‐2 signaling cascade and enhanced apoptosis in ovarian carcinoma cells

  2018cites this paper
• HER 2 Overexpression in Borderline and Malignant Ovarian Tumors : A Cross-sectional Study in an Iranian Population and Literature Review

  2018cites this paper
• Association between VEGF-A, C and D Expression and lymph Node Involvement in Breast Cancer: A Meta-Analysis

  2016influential citation
• Do preoperative serum vascular endothelial growth factor and migration-inhibitory factor predict the nature of the adnexal masses? A prospective-controlled trial

  2016cites this paper
• Disrupted Balance of MMPs/TIMPs in Gastric Carcinogenesis–Paradoxical Low MMP-2 Expression in Tumor and Stromal Compartments as a Potential Marker of Unfavorable Outcome

  2015cites this paper
• Biomedical Applications of Trastuzumab: As a Therapeutic Agent and a Targeting Ligand

  2015cites this paper
• Effect of hydrogen sulfide in comparison to atorvastatin on endothelial damage in cholesterol-fed rabbits

  2015cites this paper
• Advances in Tumor Screening, Imaging, and Avatar Technologies for High-Grade Serous Ovarian Cancer

  2014cites this paper
• Dual HER/VEGF Receptor Targeting Inhibits In Vivo Ovarian Cancer Tumor Growth

  2013cites this paper
• The anti-cancer activity of Antrodia camphorata against human ovarian carcinoma (SKOV-3) cells via modulation of HER-2/neu signaling pathway.

  2013cites this paper
• EGFR/HER-targeted therapeutics in ovarian cancer.

  2012cites this paper
• Survivin regulates the expression of VEGF-C in lymphatic metastasis of breast cancer

  2012cites this paper
• 5-Aminoisoquinolinone reduces the expression of vascular endothelial growth factor-C via the nuclear factor-κB signaling pathway in CT26 cells.

  2012cites this paper
• Chitin hydrolysate stimulates VEGF‐C synthesis by MDA‐MB‐231 breast cancer cells

  2011cites this paper
• Growth Factors and Their Receptors in Cell Differentiation, Cancer and Cancer Therapy

  2011cites this paper
• Lymphangiogenesis and lymphatic metastasis in breast cancer.

  2010cites this paper
• Expression of classical NF‐κB pathway effectors in human ovarian carcinoma

  2010cites this paper
• Expression of lymphangiogenesis marker Prox-1 in ovarian cancer

  2009cites this paper
• Clinicopathological Analysis of Lymphatic Vessels and of Lymphangiogenesis in Human Cancer

  2009cites this paper
• VEGF-A expression by HSV-1–infected cells drives corneal lymphangiogenesis

  2009cites this paper
• Reducing peritoneal vascular endothelial growth factor concentration and inhibiting cancer scattering in a mouse model of laparoscopy.

  2008cites this paper
• Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.

  2008cites this paper
• Rules of tumor cell development and their application to biomarkers for ovarian cancer.

  2008cites this paper
• Lysophosphatidic acid upregulates vascular endothelial growth factor-C and tube formation in human endothelial cells through LPA(1/3), COX-2, and NF-kappaB activation- and EGFR transactivation-dependent mechanisms.

  2008cites this paper
• Lysophosphatidic acid up-regulates vascular endothelial growth factor-C and lymphatic marker expressions in human endothelial cells

  2008cites this paper
• The impact of T‐cell immunity on ovarian cancer outcomes

  2008cites this paper
• Artemisinin Inhibits Tumor Lymphangiogenesis by Suppression of Vascular Endothelial Growth Factor C

  2008cites this paper
• Papillary thyroid carcinoma with lymph node metastases

  2007cites this paper
• INFLUÈNCIA DE LES MUTACIONS K-RAS EN EL FENOTIP ANGIOGÈNIC

  2006cites this paper
• Multimodales Management maligner Ovarialtumore

  2005cites this paper
• HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells

  2005cites this paper
• Lymphangiogenesis in human gynaecological cancers

  2005influential citation
• Etablierte und experimentelle Prognosefaktoren des Ovarialkarzinoms

  2004cites this paper
• Gene expression signature with independent prognostic significance in epithelial ovarian cancer.

  2004cites this paper
• Profiling the perpetrator.

  2004cites this paper
• Reduces the Expression of Vascular Endothelial Growth Factor-C via the Nuclear Factor-kappa B Signaling Pathway in CT26 Cells

  year unknowncites this paper